Fentanyl's Dangerous Companion Gets Scheduled—With a Transition Break

What it does

This bill adds xylazine (a veterinary sedative increasingly mixed into illicit drugs) to Schedule III of the Controlled Substances Act, making it illegal to manufacture, distribute, or possess without authorization. It permits only veterinarians, pharmacies acting on veterinary prescription, and authorized government animal-control and wildlife programs to possess it. The bill gives manufacturers and practitioners a transition period (60 days to 1 year) before full compliance with DEA security and recordkeeping rules, and requires the DEA and FDA to report on xylazine trafficking within 18 months and 4 years.

Why we flagged it

The bill's core mechanism is scheduling a dangerous drug to reduce illicit supply and protect public health. Transition provisions for industry compliance are standard regulatory practice, not the bill's character.

What the text implies

• Transition periods (60 days for practitioners, 1 year for labeling) may create a window during which xylazine remains available through legitimate channels before full enforcement; enforcement timing and DEA capacity will determine real-world impact.
• The bill exempts existing manufacturers from capital expenditure requirements for Schedule III security standards, potentially allowing continued production under weaker security than new entrants would face—a regulatory asymmetry that could affect supply-chain oversight.
• Sentencing Commission review (Section 6) is discretionary ('if appropriate'), not mandatory; sentences for xylazine trafficking may not increase, limiting deterrent effect if the Commission declines to amend guidelines.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Xylazine is a veterinary sedative increasingly mixed into heroin and fentanyl, causing severe wounds, overdose, and death; scheduling it reduces its availability in illicit drug markets and protects public health. The transition periods for manufacturers and practitioners are reasonable accommodations that do not undermine the core public-health goal.

Who stands to gain

• Veterinary pharmaceutical manufacturers (transition relief from immediate security upgrades)
• Legitimate veterinary xylazine suppliers (protected market for lawful use)

Named in the bill

Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), United States Sentencing Commission, Controlled Substances Act, Schedule III controlled substances, Veterinarians, Pharmacies

Where it stands

114 cosponsors: 63 Republicans, 51 Democrats.

• Feb 12, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 12, 2025 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a…”
• Jun 25, 2026 — Markup held in committee · Congress.gov: “Subcommittee Consideration and Mark-up Session Held”
• Jul 21, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0”
• Sep 15, 2026 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote”
• Sep 15, 2026 — Floor vote scheduled · Congress.gov: “Mr. Guthrie moved to suspend the rules and pass the bill, as amended”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 9 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $6,175,172 in lobbying spend. A filing names 21 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 82% of bills with at least one filing.

Jimmy Panetta, the sponsor, reported $1,676,556 in PAC receipts in the 2026 cycle.

• American Medical Association — $5,643,000 on 2 filings
• American Veterinary Medical Association — $384,422 on 2 filings
• Peace Officers Research Association of California — $100,000 on 2 filings
• Drug Policy Alliance — $18,639 on 1 filing
• National Association of Criminal Defense Lawyers (nacdl) — $15,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.